NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
5 trialsNCT02970318 2026-02-06
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT04666038 2025-04-20
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02005471 2023-10-17
MURANO
Hoffmann-La Roche
Phase 3 Completed
NCT02257567 2022-11-14
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed